Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2006-02-21
2006-02-21
Rao, Deepak (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C514S266200, C514S266220, C514S266240, C514S266400, C544S119000, C544S293000
Reexamination Certificate
active
07001904
ABSTRACT:
The invention concerns quinazoline and quinoline derivatives of Formula (I) wherein Q1includes a quinazoline or quinoline ring optionally substituted with a group such as halogeno, trifluoromethyl and cyano, or a group of the formula: Q3—X1— wherein X1includes a direct bond and O and Q3includes aryl, aryl-(1-6C)alkyl, heterocyclyl and heterocyclyl-(1-6C)alkyl; each of R2, R3and R5is hydrogen or (1-6C)alkyl, provides that one of the parts of groups R2and R4together, R3and R4together and R5and R4together forms a bond; R6is an optionally substituted group selected from (2-6C) alkenyl, (2-6C) alkynyl, (3-7C)cycloalkyl and (3-7C) cycloalkenyl, or R6is a substituted (1-6C) alkyl group; and Q2includes aryl and aryl-(1-3C)alkyl or a pharmaceutically-acceptable salt thereof; processes for their preparation, pharmaceutical compositions containing them and their use in the manufacture of a medicament for use in the prevention or treatment of T cell mediated diseases or medical conditions in a warm-blooded animal.
REFERENCES:
patent: 5773459 (1998-06-01), Tang et al.
patent: 6806274 (2004-10-01), Crawley et al.
patent: 95/15758 (1995-06-01), None
patent: 97/03069 (1997-01-01), None
patent: 98/38984 (1998-09-01), None
patent: 98/50047 (1998-11-01), None
patent: 98/50370 (1998-11-01), None
patent: 98/52558 (1998-11-01), None
patent: 99/09024 (1999-02-01), None
patent: 01/04102 (2001-01-01), None
Casanova et al., PubMed Abstract (Rev Neurol 28(9):909-15), May 1999.
Gibson et al., “Epidermal growth factor receptor tyrosine kinase: structure-activity relationships and antitumour activity of novel quinazolines”, Bioorganic & Medicinal Chemistry Letters, vol. 7, No. 21, Nov. 4, 1997, pp. 2723-2728, XP004136520, ISSN: 0960-894X.
Hong et al.; “Synthesis and Billogical Activities of Some N4-Substituted 4-Aminopyrazolo 3,4-d-pyrimidines”; Journal of Medicinal Chemistry, 1976, vol. 19, No. 4, pp. 555-558.
Myers et al.; “The Preparation and SAR of 4-(Anilino), 4-(Phenoxy), and 4-Thiophenoxy)-Quinazolines: Inhibitors of p56ickand EGF-R Tyrosine Kinase Activity”; Bioorganic & Medicinal Chemistry Letters, 1997, vol. 7, No. 4, pp. 417-420.
van Muijlwijk-Koezen et al.; “Isoquinoline and Quinazoline Urea Analogues as Antagonists for the Human Adenosine A3Receptor”; J. Med. Chem., 2000, vol. 43, pp. 2227-2238.
AstraZeneca AB
Morgan & Lewis & Bockius, LLP
Rao Deepak
LandOfFree
Guanidine derivatives quinazoline and quinoline for use in... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Guanidine derivatives quinazoline and quinoline for use in..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Guanidine derivatives quinazoline and quinoline for use in... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3710195